By Hendra Lukman 
A groundbreaking advancement in stem cell transplantation has emerged from Stanford Medicine, offering a radical departure from conventional, toxicity-laden preparatory regimens. Researchers have successfully demonstrated, through a Phase 1 clinical trial, that a novel antibody therapy can effectively condition patients for stem cell transplants without the necessity of harsh chemotherapy or radiation. This innovative approach holds immense promise, particularly for individuals with rare genetic disorders like Fanconi anemia, where traditional transplant protocols pose significant risks. The findings, published in the prestigious journal Nature Medicine, signal a potential paradigm shift in transplant medicine, paving the way for safer and more accessible treatments for a wider range of debilitating diseases.
A New Era for Stem Cell Transplants: Eliminating Toxic Conditioning
The cornerstone of this revolutionary treatment lies in an antibody that targets a specific protein found on blood-forming stem cells. This antibody, identified as briquilimab, has proven capable of selectively eliminating a patient’s own unhealthy stem cells, a crucial prerequisite for successful transplantation. Traditionally, this preparatory phase, known as conditioning, has relied on cytotoxic agents like radiation and genotoxic chemotherapy, most notably busulfan. These treatments, while effective in clearing existing stem cells, carry a heavy burden of toxicity, leading to severe side effects, increased risk of secondary cancers, and long-term health complications.
"We were able to treat these really fragile patients with a new, innovative regimen that allowed us to reduce the toxicity of the stem cell transplant protocol," explained Agnieszka Czechowicz, MD, PhD, assistant professor of pediatrics and co-senior author of the study. "Specifically, we could eliminate the use of radiation and genotoxic chemotherapy called busulfan, with exceptional outcomes." This elimination of toxic conditioning is not merely an incremental improvement; it represents a fundamental redesign of the transplant process, prioritizing patient well-being and minimizing the collateral damage associated with conventional methods.
The clinical trial specifically focused on children with Fanconi anemia, a rare, inherited blood disorder characterized by progressive bone marrow failure. This condition severely compromises the body’s ability to produce essential blood cells, leading to a heightened risk of bleeding and life-threatening infections. For these patients, a stem cell transplant is often the only viable curative option. However, the vulnerability of their compromised systems made the toxicity of traditional conditioning regimens particularly perilous.
"If they don’t get a transplant in time, Fanconi anemia patients’ bodies eventually will not make blood, so they die of bleeding or infections," elaborated Rajni Agarwal, MD, professor of pediatric stem cell transplantation and co-first author. "The reason I am so excited about this trial is that it is a novel approach to help these patients, who are very vulnerable." The success in these fragile patients suggests a broad applicability of the antibody-based approach to other inherited diseases requiring stem cell transplants, potentially expanding the reach of this life-saving therapy.
The Science Behind the Breakthrough: Targeting CD117
The antibody briquilimab functions by targeting CD117, a protein that serves as a key marker on hematopoietic (blood-forming) stem cells. By binding to CD117, the antibody effectively neutralizes these cells, preventing them from regenerating. This targeted approach ensures that only the intended stem cells are affected, leaving other vital cells and tissues largely unharmed.
This innovative strategy builds upon decades of pioneering research at Stanford Medicine, spearheaded by luminaries like Irving Weissman, MD. As far back as 2004, Dr. Weissman and his team were investigating the potential of blocking CD117 with antibodies to eliminate stem cells in mice, demonstrating the feasibility of a non-toxic conditioning method. The subsequent development and refinement of an antibody suitable for human clinical use, culminating in the briquilimab trial, represent a significant translation of basic science into tangible clinical benefit.
The trial meticulously documented the efficacy and safety of this novel regimen. Three children diagnosed with Fanconi anemia underwent the modified transplant procedure. The antibody was administered as a single intravenous dose approximately 12 days prior to the stem cell infusion. Following this, patients received standard immune-suppressing medications, but notably, no busulfan or radiation was administered.
The results were remarkably positive. Within two weeks of receiving the donated stem cells, the new cells had successfully engrafted in the patients’ bone marrow. Crucially, none of the participants experienced graft rejection, a common complication in transplantation. By one month post-transplant, the donor cells had almost entirely replaced the patients’ own bone marrow stem cells. The research team’s initial goal was to achieve just 1% donor cell presence, a modest target for a novel approach. However, astonishingly, all three children achieved nearly 100% donor cell chimerism, indicating a complete and robust reconstitution of their blood-forming systems.
"We’ve been surprised by how well it’s worked," stated Dr. Czechowicz. "We were optimistic that we would get here, but you never know when you’re trying a new regimen." The sustained positive outcomes have been tracked for two years, with all three children continuing to thrive.
Addressing Donor Shortages: Expanding Transplant Accessibility
Beyond revolutionizing the conditioning process, the Stanford team also addressed another significant hurdle in stem cell transplantation: the persistent shortage of fully matched donors. Historically, a substantial percentage of patients, estimated to be as high as 40%, have been unable to proceed with transplants due to the inability to find a compatible donor. This scarcity has tragically led to prolonged waiting times and, in some cases, a complete denial of life-saving treatment.
To overcome this challenge, the researchers implemented a sophisticated modification of the donor bone marrow. This process involved enriching the donated marrow for CD34+ cells, which are the essential blood-forming stem cells, while simultaneously depleting immune cells known as alpha/beta T-cells. The removal of these T-cells is critical as they are the primary culprits behind graft-versus-host disease (GVHD), a severe and potentially fatal complication where the donor’s immune system attacks the recipient’s body.
This innovative approach, pioneered by Alice Bertaina, MD, PhD, a key collaborator on the study, enables safe and effective transplants from half-matched donors, including biological parents. This significantly broadens the pool of potential donors, dramatically increasing the likelihood that any given patient can find a compatible source of healthy stem cells.
"We are expanding the donors for stem cell transplantation in a major way, so every patient who needs a transplant can get one," affirmed Dr. Agarwal. This dual advancement—a safer conditioning regimen and an expanded donor pool—collectively transforms the landscape of stem cell transplantation, making it a more viable and accessible option for a much larger patient population.
A Child’s Journey: Ryder’s Inspiring Recovery
The profound impact of this new therapy is vividly illustrated by the story of Ryder Baker, an 11-year-old boy from Seguin, Texas, who was the first child to receive the treatment. Diagnosed with Fanconi anemia, Ryder’s life was significantly impacted by the debilitating effects of his condition, including profound fatigue and a compromised immune system.
Following the modified stem cell transplant performed at Lucile Packard Children’s Hospital Stanford in early 2022, Ryder has experienced a remarkable transformation. His mother, Andrea Reiley, shared her profound relief and joy at her son’s recovery. "He was so tired, he didn’t have stamina. It’s completely different now," she said, noting that her son’s Fanconi anemia "doesn’t slow him down like it used to."
Ryder’s newfound energy has allowed him to fully re-engage with life. He recently completed fifth grade, participates actively in sports, and was even recognized with an "Up and Coming Player" award from his school soccer team. This personal triumph underscores the life-altering potential of the antibody-based therapy, not just in terms of survival, but in restoring quality of life and enabling children to experience a normal childhood.
"It was heartbreaking to see him go through things like that — I’d rather go through it than my child," Ms. Reiley confessed, reflecting on the difficult journey. "I felt the heartbreak for him, and now he doesn’t have to." Since his recovery, Ryder has experienced significant physical growth, gained weight, and is no longer plagued by frequent illnesses, a constant source of worry for his parents. Ms. Reiley also shared that Ryder takes pride in his role as one of the first patients, understanding that his experience is helping to pave the way for future children.
Broader Implications and Future Directions
The success of this Phase 1 trial opens exciting avenues for future research and clinical application. While the primary focus has been on Fanconi anemia, researchers are optimistic about extending this antibody-based conditioning strategy to other rare bone marrow failure syndromes, such as Diamond-Blackfan anemia.
Furthermore, the implications for cancer patients are significant. Although most cancer patients undergoing stem cell transplants require chemotherapy or radiation to eradicate malignant cells, the Stanford team is exploring whether the antibody approach could benefit elderly cancer patients who may not tolerate the rigors of traditional conditioning. This could provide a less intense, yet effective, conditioning option, thereby expanding transplant eligibility to a vulnerable population often excluded due to age or comorbidities.
"That population is often at a disadvantage," explained Dr. Agarwal. "It may provide us with a way to treat them with less intensity so it’s possible for them to get a transplant." The team is also actively developing next-generation antibody-based treatments aimed at further refining outcomes and improving the efficacy of transplants for a wider spectrum of diseases.
The journey from laboratory discovery to clinical application has been a long and dedicated one, spanning over three decades of research at Stanford Medicine. The collaborative efforts involved researchers from institutions including the University of California, San Francisco; Kaiser Permanente Bernard J. Tyson School of Medicine; St. Jude Children’s Research Hospital; Memorial Sloan Kettering Cancer Center; and Jasper Therapeutics Inc. The research was supported by funding from anonymous donors, the California Institute of Regenerative Medicine, and the Fanconi Cancer Foundation, with Jasper Therapeutics providing the crucial antibody, briquilimab.
The introduction of this antibody-based therapy marks a pivotal moment in the evolution of stem cell transplantation. By mitigating the severe toxicities associated with traditional conditioning regimens and simultaneously addressing donor shortages, Stanford Medicine is ushering in an era of safer, more accessible, and ultimately, more life-saving transplants for patients facing a range of devastating diseases. The profound impact on young patients like Ryder Baker serves as a powerful testament to the transformative potential of scientific innovation driven by a commitment to improving human health.
